Phase II IMC-A12 in children with relapsed/refractory solid tumors
Rhabdomyosarcoma · Synovial Sarcoma · Recurrent Osteosarcoma · Recurrent Neuroblastoma
Enrolment: 116 · Results not recorded
Loading the evidence…
Biologic · ANTAGONIST: Insulin-like growth factor I receptor antagonist. Binds IGF-1R with high affinity, blocks interaction with IGF-1 and IGF-II, and induces internalisation and degradation of IGF-1R.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Rhabdomyosarcoma · Synovial Sarcoma · Recurrent Osteosarcoma · Recurrent Neuroblastoma
Enrolment: 116 · Results not recorded
Ewing's Sarcoma/PNET · Rhabdomyosarcoma · Leiomyosarcoma · Adipocytic Sarcoma · Synovial Sarcoma
Enrolment: 113 · Results not recorded
Head and Neck Cancer
Enrolment: 97 · Results not recorded
Metastatic Oesophageal Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Enrolment: 94 · Results not recorded
Adenocarcinoma of the Prostate
Enrolment: 41 · Results not recorded
Metastatic Intraocular Melanoma
Enrolment: 18 · Results not recorded
Colorectal Cancer
Enrolment: 65 · Results not recorded
Recurrent Ewing Sarcoma/PNET · Childhood Solid Tumour
Enrolment: 34 · Results not recorded
Malignant Neoplasm
Enrolment: 72 · Results not recorded
Neuroendocrine Tumour · Merkel Cell Carcinoma
Enrolment: 27 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Exposure to 95% hyperoxia for 88-90 hours causing acute lung injury
A12 significantly decreased bronchoalveolar lavage polymorphonuclear cell count compared with control antibody (P = 0.02) and lavage fluid from A12-treated mice showed reduced neutrophil chemotactic activity. There were no differences in CXCL1 or CXCL2.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.